Haemonetics Corp (HAE) reported robust financial results for the second quarter of fiscal 2026, surpassing analyst expectations. The company's earnings per share (EPS) reached $1.27, exceeding the consensus estimate of $1.12 by $0.15. Revenue matched expectations at $0.3 billion.
This update provides insight into Haemonetics' operational performance and financial health. The firm, headquartered in Boston, Massachusetts, develops and distributes hematology products and solutions, employing 3,023 full-time staff. Its offerings span various medical markets, including blood and plasma component collection, surgical suites, and hospital transfusion services.
The company will host an earnings conference call at bmo to discuss these results and provide further commentary on business performance. Investors are encouraged to review the complete earnings release for a comprehensive understanding of the quarter's performance and future outlook.
Looking ahead, Haemonetics is scheduled to report its next earnings on 4 August 2026, with EPS and revenue estimates of $1.286 and $0.3 billion, respectively.
With a market capitalisation of $3,381.56 million and a trailing P/E ratio of 20.7, Haemonetics continues to navigate the healthcare sector's complexities while aiming to enhance patient care and reduce healthcare costs.